Vise Technologies Inc. Invests $584,000 in Puma Biotechnology, Inc. $PBYI

Vise Technologies Inc. acquired a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 72,030 shares of the biopharmaceutical company’s stock, valued at approximately $584,000. Vise Technologies Inc. owned approximately 0.14% of Puma Biotechnology as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in Puma Biotechnology by 244.5% during the first quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 3,066 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Puma Biotechnology by 39.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 2,290 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Puma Biotechnology in the 4th quarter valued at $49,000. State of Alaska Department of Revenue bought a new position in shares of Puma Biotechnology in the 4th quarter worth $50,000. Finally, ProShare Advisors LLC bought a new position in shares of Puma Biotechnology in the 4th quarter worth $60,000. 61.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on PBYI. Weiss Ratings raised Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday. TD Cowen boosted their target price on shares of Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a report on Friday, August 7th. Finally, Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.00.

Puma Biotechnology Trading Down 1.3%

Shares of PBYI opened at $9.12 on Tuesday. Puma Biotechnology, Inc. has a 12 month low of $4.30 and a 12 month high of $9.51. The stock has a fifty day moving average price of $8.23 and a 200-day moving average price of $7.37. The firm has a market cap of $470.77 million, a PE ratio of 17.54 and a beta of 1.22.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.15. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%.The firm had revenue of $56.50 million for the quarter, compared to the consensus estimate of $53.00 million. As a group, research analysts forecast that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Insider Buying and Selling at Puma Biotechnology

In other news, insider Douglas M. Hunt sold 8,460 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $8.26, for a total transaction of $69,879.60. Following the transaction, the insider owned 196,841 shares in the company, valued at $1,625,906.66. This represents a 4.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian Senderowicz sold 27,000 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $194,400.00. Following the completion of the transaction, the director directly owned 27,000 shares of the company’s stock, valued at $194,400. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 132,028 shares of company stock valued at $1,006,711. Insiders own 22.20% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.